High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial
<p>Abstract</p> <p>Background</p> <p>The use of Lamivudine in chronic hepatitis B (CHB) is well known, however the reported rate of HBeAg sero-conversion and its durability post-treatment have varied considerably. We undertook the present study to study the effect of La...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2005-09-01
|
| Series: | BMC Gastroenterology |
| Online Access: | http://www.biomedcentral.com/1471-230X/5/29 |